AbCellera Biologics (ABCL) to Release Earnings on Monday

AbCellera Biologics (NASDAQ:ABCLGet Free Report) will be issuing its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect AbCellera Biologics to post earnings of ($0.14) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCLGet Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. AbCellera Biologics had a negative net margin of 463.77% and a negative return on equity of 13.40%. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $10.12 million. During the same period in the previous year, the business posted ($0.11) earnings per share. The firm’s quarterly revenue was down 27.7% compared to the same quarter last year. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Performance

ABCL opened at $2.73 on Friday. The firm’s 50 day simple moving average is $2.62 and its two-hundred day simple moving average is $3.07. The company has a market capitalization of $804.44 million, a PE ratio of -5.06 and a beta of 0.35. AbCellera Biologics has a 1-year low of $2.34 and a 1-year high of $6.05.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ABCL shares. Benchmark downgraded AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. KeyCorp reiterated an “overweight” rating and set a $5.00 price objective (down from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th.

Get Our Latest Stock Analysis on AbCellera Biologics

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

See Also

Earnings History for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.